InspireMD (STU:II2) Cyclically Adjusted Revenue per Share: €123.57 (As of Mar. 2026)


STU:II2 InspireMD Inc STU:II2
41 GF Score
Price €0.62
GF Value €1.53
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is InspireMD Cyclically Adjusted Revenue per Share?

InspireMD STU:II2 +1.64% 41 Cyclically Adjusted Revenue per Share is €123.57 as of Mar. 2026. GuruFocus rates STU:II2 with a GF Score™ of 41/100 and a GF Value™ of €1.53 (Possible Value Trap). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

InspireMD's adjusted revenue per share for the three months ended in Mar. 2026 was €0.035. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €123.57 for the trailing ten years ended in Mar. 2026.

During the past 12 months, InspireMD's average Cyclically Adjusted Revenue Growth Rate was -8.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -11.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -13.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of InspireMD was -11.40% per year. The lowest was -30.20% per year. And the median was -15.00% per year.

As of today (2026-07-08), InspireMD's current stock price is €0.62. InspireMD's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €123.57. InspireMD's Cyclically Adjusted PS Ratio of today is 0.01.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of InspireMD was 0.21. The lowest was 0.01. And the median was 0.02.


InspireMD  (STU:II2) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

InspireMD's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.62/123.57
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of InspireMD was 0.21. The lowest was 0.01. And the median was 0.02.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


InspireMD Cyclically Adjusted Revenue per Share Related Terms


InspireMD Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for InspireMD's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InspireMD Cyclically Adjusted Revenue per Share Chart

InspireMD Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 489.73 200.66 154.83 156.70 130.17

InspireMD Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 145.30 133.64 129.12 130.17 123.57

STU:II2 vs TELA, BDMD, PAVM: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, InspireMD's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InspireMD Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, InspireMD's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where InspireMD's Cyclically Adjusted PS Ratio falls into.


STU:II2
41GF Score
InspireMD Inc STU:II2
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InspireMD Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, InspireMD's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.035/330.2130*330.2130
=0.035

Current CPI (Mar. 2026) = 330.2130.

InspireMD Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.000 241.018 0.000
201609 0.000 241.428 0.000
201612 0.000 241.432 0.000
201703 0.000 243.801 0.000
201706 0.000 244.955 0.000
201709 0.000 246.819 0.000
201712 352.500 246.524 472.165
201803 272.333 249.554 360.354
201806 95.444 251.989 125.072
201809 12.204 252.439 15.964
201812 14.176 251.233 18.633
201903 6.554 254.202 8.514
201906 13.022 256.143 16.788
201909 7.755 256.759 9.974
201912 3.494 256.974 4.490
202003 3.039 258.115 3.888
202006 0.329 257.797 0.421
202009 0.358 260.280 0.454
202012 0.040 260.474 0.051
202103 0.138 264.877 0.172
202106 0.112 271.696 0.136
202109 0.118 274.310 0.142
202112 0.157 278.802 0.186
202203 0.138 287.504 0.159
202206 0.185 296.311 0.206
202209 0.184 296.808 0.205
202212 0.121 296.797 0.135
202303 0.143 301.836 0.156
202306 0.072 305.109 0.078
202309 0.043 307.789 0.046
202312 0.048 306.746 0.052
202403 0.041 312.332 0.043
202406 0.045 314.175 0.047
202409 0.034 315.301 0.036
202412 0.038 315.605 0.040
202503 0.028 319.799 0.029
202506 0.030 322.561 0.031
202509 0.029 324.800 0.029
202512 0.033 324.054 0.034
202603 0.035 330.213 0.035

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €123.57 mean?
InspireMD (STU:II2) has a Cyclically Adjusted Revenue per Share of €123.57 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on InspireMD and its competitors.
Is InspireMD's Cyclically Adjusted Revenue per Share too high?
InspireMD's current Cyclically Adjusted Revenue per Share is €123.57. Overall, InspireMD has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InspireMD's Cyclically Adjusted Revenue per Share compare to TELA and BDMD?
InspireMD's Cyclically Adjusted Revenue per Share of €123.57 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on InspireMD and its competitors. InspireMD's current Cyclically Adjusted Revenue per Share is €123.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InspireMD stock overvalued right now?
Based on GuruFocus' analysis, InspireMD (STU:II2) is currently considered Possible Value Trap. The stock's GF Value™ is €1.53, compared to a current price of €0.62 — trading 59.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €123.57. InspireMD's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For InspireMD (STU:II2), the current Cyclically Adjusted Revenue per Share is €123.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InspireMD (STU:II2) Overvalued in 2026?

Based on GuruFocus' analysis, InspireMD stock appears to be undervalued. The current stock price of €0.62 is trading 59.5% below its estimated GF Value™ of €1.53. GuruFocus considers InspireMD to be Possible Value Trap.

Key valuation signals for STU:II2:

  • Cyclically Adjusted Revenue per Share: €123.57
  • GF Value™: €1.53 vs. price of €0.62 (59.5% below fair value)
  • GF Score™: 41/100 with 3 warning signs

No single metric tells the full story. See the STU:II2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


InspireMD Business Description

Other Exchanges NSPR:USA
Address 6303 Waterford District Drive, Suite 215, Miami, FL, USA, 33126
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
41GF Score

Get the complete analysis for STU:II2

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.62
Price
€1.53
GF Value